Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | ATM | Q13315 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19090254 | 1.00 | KMT2A (0.68) | KMT2AMEN1ATMMAPTHSD17B10 | |
| SCHEMBL2489191 | 1.00 | KMT2A (0.68) | KMT2AMEN1ATMMAPTHSD17B10 | |
| SCHEMBL4711685 | 0.98 | MEN1 (0.73) | KMT2AMEN1ATMMAPTHSD17B10 | |
| SCHEMBL17934932 | 0.98 | MEN1 (0.73) | KMT2AMEN1ATMMAPTHSD17B10 | |
| SCHEMBL18623991 | 0.98 | MEN1 (0.73) | KMT2AMEN1ATMMAPTHSD17B10 | |
| SCHEMBL11892772 | 0.95 | — | — | |
| SCHEMBL11892695 | 0.95 | — | — | |
| SCHEMBL2801641 | 0.90 | KMT2A (0.52) | KMT2AMEN1ATMMAPTHSD17B10 | |
| SCHEMBL25303574 | 0.84 | MEN1 (0.55) | KMT2AMEN1ATMMAPTHSD17B10 | |
| SCHEMBL10895166 | 0.84 | MEN1 (0.94) | KMT2AMEN1ATMMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| CN-112384500-A | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| EP-2176250-B1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2176250-B1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| EP-2176250-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| EP-2019100-A1 | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| EP-2019100-A1 | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| WO-2009010299-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010299-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | SMYD3, SMYD2, SNRPD3 | KMT2A 580/4885MEN1 3284/4885ATM 1643/4885 |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | KMT2A 838/4885MEN1 1716/4885ATM 2526/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | KMT2A 348/4885MEN1 3278/4885ATM 2613/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | KMT2A 355/4885MEN1 3280/4885ATM 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.